These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 37732005)

  • 1. Digital Health Applications (DiHA): Approaches to develop a reimbursement process for the statutory health insurance in Austria.
    Goetz G; Jeindl R; Panteli D; Busse R; Wild C
    Health Policy Technol; 2023 Sep; 12(3):None. PubMed ID: 37732005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefit Assessment and Reimbursement of Digital Health Applications: Concepts for Setting Up a New System for Public Coverage.
    Lantzsch H; Panteli D; Martino F; Stephani V; Seißler D; Püschel C; Knöppler K; Busse R
    Front Public Health; 2022; 10():832870. PubMed ID: 35530738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Digital health applications and the fast-track pathway to public health coverage in Germany: challenges and opportunities based on first results.
    Lantzsch H; Eckhardt H; Campione A; Busse R; Henschke C
    BMC Health Serv Res; 2022 Sep; 22(1):1182. PubMed ID: 36131288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The new approval process for the reimbursement of digital health applications (DiGA) from the perspective of the German statutory health insurance].
    Gregor-Haack J; Busse T; Hagenmeyer EG
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2021 Oct; 64(10):1220-1227. PubMed ID: 34459939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence requirements of permanently listed digital health applications (DiGA) and their implementation in the German DiGA directory: an analysis.
    Mäder M; Timpel P; Schönfelder T; Militzer-Horstmann C; Scheibe S; Heinrich R; Häckl D
    BMC Health Serv Res; 2023 Apr; 23(1):369. PubMed ID: 37069592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Market access and value-based pricing of digital health applications in Germany.
    Gensorowsky D; Witte J; Batram M; Greiner W
    Cost Eff Resour Alloc; 2022 Jun; 20(1):25. PubMed ID: 35698135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Reimbursement of health apps by the German statutory health insurance].
    Gregor-Haack J
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2018 Mar; 61(3):328-333. PubMed ID: 29374299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Digital health applications: statutory introduction of patient-centred digital innovations into healthcare].
    Ludewig G; Klose C; Hunze L; Matenaar S
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2021 Oct; 64(10):1198-1206. PubMed ID: 34529096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation criteria for health apps supporting medication adherence in early-stage technology development - a scoping review.
    Niemann A; Hüer T; Neumann A; Wasem J; Schnell-Inderst P; Neusser S
    Ger Med Sci; 2023; 21():Doc03. PubMed ID: 37260918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methods for the comparative evaluation of pharmaceuticals.
    Zentner A; Velasco-Garrido M; Busse R
    GMS Health Technol Assess; 2005 Nov; 1():Doc09. PubMed ID: 21289930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of digital health applications for the detection of atrial fibrillation.
    Lawin D; Kuhn S; Schulze Lammers S; Lawrenz T; Stellbrink C
    Herzschrittmacherther Elektrophysiol; 2022 Dec; 33(4):373-379. PubMed ID: 35960358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Individual health services.
    Schnell-Inderst P; Hunger T; Hintringer K; Schwarzer R; Seifert-Klauss VR; Gothe H; Wasem J; Siebert U
    GMS Health Technol Assess; 2011; 7():Doc05. PubMed ID: 21966301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [How can the impact of Health Technology Assessment (HTA) in the Austrian healthcare system be assessed? Design of a conceptual framework].
    Schumacher I; Zechmeister I
    Gesundheitswesen; 2012 Apr; 74(4):257-65. PubMed ID: 21267815
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.